ShareValue scores for 0GZK.LSE: Valuation 33, Quality 50, Growth 50, Health 45.

0GZK.LSE
LSE

Ion Beam Applications S.A.

£0.16(-0.86%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-6% to 10%
Valuation
33
Overvalued
Price vs Value
Quality
50
Moderate
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
45
Moderate
Financial Stability
Momentum
94
Bullish
Price Trend

Company Details

About

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally. It operates through Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. It also develops ConformalFLASH, a novel technique using the proton Bragg peak. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026